Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

replimune group - REPL

REPL

Close Chg Chg %
14.38 -0.33 -2.29%

Open Market

14.05

-0.33 (2.29%)

Volume: 1.31M

Last Updated:

Nov 27, 2024, 4:00 PM EDT

Trade Now

Company Overview: replimune group - REPL

REPL Key Data

Open

$14.38

 Day Range

13.80 - 14.64

52 Week Range

4.92 - 16.55

 Market Cap

$983.84M

Shares Outstanding

68.42M

 Public Float

54.44M

Beta

1.19

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.12

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

986.36K

  

REPL Performance

1 Week
 
 -5.89%
 
1 Month
 
 18.07%
 
3 Months
 
 38.15%
 
1 Year
 
 19.98%
 
5 Years
 
 1.08%
 

REPL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About replimune group - REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

REPL At a Glance

Replimune Group, Inc.
500 Unicorn Park Drive
Woburn, Massachusetts 01801
Phone 1-781-222-9600 Revenue 0.00
Industry Biotechnology Net Income -215,794,000.00
Sector Health Technology Employees 331
Fiscal Year-end 03 / 2025
View SEC Filings

REPL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 1.34
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.851
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.381

REPL Efficiency

Revenue/Employee N/A
Income Per Employee -651,945.619
Receivables Turnover N/A
Total Asset Turnover N/A

REPL Liquidity

Current Ratio 10.724
Quick Ratio 10.724
Cash Ratio 10.403

REPL Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -38.048
Return on Equity -46.417
Return on Total Capital -47.914
Return on Invested Capital -40.762

REPL Capital Structure

Total Debt to Total Equity 20.258
Total Debt to Total Capital 16.846
Total Debt to Total Assets 15.556
Long-Term Debt to Equity 19.223
Long-Term Debt to Total Capital 15.984
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Replimune Group - REPL

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
4.14M 4.58M 2.45M 2.65M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.14M 4.58M 2.45M 2.65M
Depreciation
4.14M 4.58M 2.45M 2.65M
Amortization of Intangibles
- - - -
-
COGS Growth
+129.05% +10.53% -46.51% +8.50%
Gross Income
(4.14M) (4.58M) (2.45M) (2.65M)
Gross Income Growth
-129.05% -10.53% +46.51% -8.50%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
78.62M 116.91M 177.55M 234.04M
Research & Development
57.49M 80.64M 129.44M 176.88M
Other SG&A
21.13M 36.26M 48.11M 57.16M
SGA Growth
+36.80% +48.70% +51.87% +31.82%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 913.00K
-
EBIT after Unusual Expense
(83.67M) (121.48M) (179.99M) (236.69M)
Non Operating Income/Expense
3.06M 2.50M 7.24M 26.05M
Non-Operating Interest Income
916.00K 390.00K 10.01M 23.36M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.06M 2.22M 4.16M 6.66M
Interest Expense Growth
+59.46% -27.35% +87.13% +60.10%
Gross Interest Expense
3.06M 2.22M 4.16M 6.66M
Interest Capitalized
- - - -
-
Pretax Income
(83.68M) (121.21M) (176.91M) (217.31M)
Pretax Income Growth
-50.20% -44.85% -45.96% -22.83%
Pretax Margin
- - - -
-
Income Tax
(2.81M) (3.17M) (2.63M) (1.51M)
Income Tax - Current - Domestic
- - 288.00K 408.00K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
2.81M 3.17M 2.91M 1.92M
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(80.87M) (118.04M) (174.28M) (215.79M)
Minority Interest Expense
- - - -
-
Net Income
(80.87M) (118.04M) (174.28M) (215.79M)
Net Income Growth
-53.67% -45.96% -47.65% -23.82%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(80.87M) (118.04M) (174.28M) (215.79M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(80.87M) (118.04M) (174.28M) (215.79M)
EPS (Basic)
-1.7486 -2.2607 -2.9939 -3.2416
EPS (Basic) Growth
-13.84% -29.29% -32.43% -8.27%
Basic Shares Outstanding
46.25M 52.21M 58.21M 66.57M
EPS (Diluted)
-1.7486 -2.2607 -2.9939 -3.2416
EPS (Diluted) Growth
-13.84% -29.29% -32.43% -8.27%
Diluted Shares Outstanding
46.25M 52.21M 58.21M 66.57M
EBITDA
(78.62M) (116.91M) (177.55M) (234.04M)
EBITDA Growth
-36.80% -48.70% -51.87% -31.82%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 16.00
Number of Ratings 9 Current Quarters Estimate -0.763
FY Report Date 12 / 2024 Current Year's Estimate -2.922
Last Quarter’s Earnings -0.68 Median PE on CY Estimate N/A
Year Ago Earnings -3.24 Next Fiscal Year Estimate -2.675
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 8 6
Mean Estimate -0.76 -0.75 -2.92 -2.68
High Estimates -0.71 -0.61 -2.30 -2.28
Low Estimate -0.82 -0.88 -3.35 -3.08
Coefficient of Variance -6.09 -12.28 -10.68 -10.51

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 9
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Replimune Group - REPL

Date Name Shares Transaction Value
Aug 20, 2024 Emily Hill Chief Financial Officer 101,057 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.18 per share 1,028,760.26
Jun 11, 2024 Konstantinos Xynos Chief Medical Officer 117,131 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.5 per share 878,482.50
May 21, 2024 Robert Coffin Director 1,821,872 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.47 per share 11,787,511.84
May 21, 2024 Philip Astley-Sparke Executive Chairman; Director 1,487,350 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.47 per share 9,623,154.50
May 21, 2024 Colin A. Love Chief Operating Officer 777,345 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.47 per share 5,029,422.15
May 21, 2024 Sushil Patel Chief Executive Officer; Director 212,014 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.47 per share 1,371,730.58
May 21, 2024 Christopher Sarchi Chief Commercial Officer 92,252 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.47 per share 596,870.44
May 21, 2024 Andrew Schwendenman Chief Accounting Officer 38,238 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.47 per share 247,399.86

Replimune Group in the News